Study Provides Technology Insights to Improve Patient Engagement
A Greenphire study of 600 clinical trial professionals from various stakeholders weigh in on emerging patient engagement trends
Greenphire has released its global 2023 State of Clinical Trial Patient Convenience Market Trends survey, providing insights from 600 clinical trial sites, sponsors, and CRO personnel are responding to emerging trends for patient engagement.
Key highlights include:
Patient Tech Accessibility – 90% of sponsors and 86% of sites agree that it is important for participants in a clinical trial to have access to the study information digitally via web or mobile applications (such as a phone or tablet).
44% of sponsors agree that having the opportunity to complete a participant experience survey in order to gain insights on feedback is very important.
Financial Accessibility – 93% of sites and sponsors agree that ensuring study volunteers, both with and without bank accounts, can be easily reimbursed for out-of-pocket expenses.
Location Accessibility – 90% of sites and 95% of sponsors agree that removing financial and logistical barriers from patient participation in clinical trials can improve retention.
The full survey results are available for free download.
Reference: New Greenphire Study Finds Unified Technology Essential for Enhancing Patient Experience and Engagement in Clinical Trials. KING OF PRUSSIA, Pa., July 12, 2023.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
